Analyzing cell-free DNA for cancer detection
Cell-free DNA Analysis for Liquid Biopsy of Cancer
This study is looking at blood samples from people with non-small cell lung cancer to find new ways to spot the disease early and track its changes, using a special method that can catch important genetic clues that other tests might miss.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10924016 on NIH RePORTER |
What this research studies
This research focuses on analyzing circulating tumor DNA (ctDNA) found in the blood of patients with non-small cell lung carcinoma (NSCLC) to improve early detection and genetic monitoring of the disease. The study utilizes a novel electric field-induced release and measurement liquid biopsy (eLB) platform, which can detect specific mutations in ctDNA that are often missed by traditional methods. By examining ultrashort single-stranded ctDNA, the research aims to uncover new insights that could lead to better treatment options and improved patient outcomes. Patients will provide plasma samples that will be analyzed using advanced sequencing techniques and bioinformatics.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with late-stage non-small cell lung carcinoma who have specific EGFR mutations.
Not a fit: Patients with early-stage lung cancer or those without EGFR mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate detection of NSCLC, ultimately improving treatment strategies and survival rates for patients.
How similar studies have performed: Previous research has shown promise in using liquid biopsy techniques for cancer detection, but this specific approach utilizing ultrashort ctDNA is novel.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Cheng, Jordan C — Stanford University
- Study coordinator: Cheng, Jordan C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.